HCP Connect Contributor
Dr. Amit Desai
Dr. Amit Desai contributes endocrinology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.
Recent Drug Updates
46 total
Endocrinology
GLP-1 Receptor Agonists 2026: Comprehensive Comparison of Orforglipron, Tirzepatide, and Semaglutide
WHO guidelines update on GLP-1 receptor agonists: orforglipron, tirzepatide, semaglutide for obesity treatment.
Endocrinology
ADA Updates Diabetes Treatment Guidelines: GLP-1 and SGLT2 Prioritized for Cardiovascular and Kidney Outcomes
ADA updates diabetes treatment guidelines emphasizing GLP-1 and SGLT2 inhibitors for improved cardiovascular and kidney outcomes.
Endocrinology
FDA Approves Langlara: New Biosimilar Insulin for Cost-Effective Diabetes Management
FDA approves Langlara for diabetes management: a cost-effective biosimilar insulin enhancing patient access.
Endocrinology
FDA Approves Afrezza for Pediatric Use: First Needle-Free Insulin for Kids Ages 4 and Up
FDA approves Afrezza for pediatric diabetes: first needle-free insulin for kids ages 4 and up.
Endocrinology
WHO Releases 2026 Guidelines for GLP-1 Therapies in Obesity Management
WHO releases guidelines on GLP-1 therapies for obesity management, emphasizing comprehensive treatment strategies.
Endocrinology
FDA Proposes Exclusion of Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List
FDA proposes exclusion of semaglutide, tirzepatide, and liraglutide from 503B bulks list, affecting clinical practices and patient treatment options.
Endocrinology
FDA Approves Orforglipron for Obesity: Oral GLP-1 Therapy with No Food Restrictions
FDA approves orforglipron for obesity: oral GLP-1 therapy with no food restrictions, improving patient compliance and treatment outcomes.
Endocrinology
FDA Approves Afrezza for Pediatric Use: First Needle-Free Insulin for Children with Diabetes
FDA approves Afrezza for pediatric use: first needle-free insulin for children with diabetes.
Endocrinology
FDA Approves Langlara and Ponlimsi: New Biosimilars for Insulin Access
FDA approves Langlara and Ponlimsi biosimilars, enhancing insulin access for diabetes management.
Endocrinology
FDA Proposes Exclusion of Semaglutide and Tirzepatide from 503B Bulks List: Impact on Compounding Access
FDA proposes exclusion of semaglutide and tirzepatide from 503B bulks list, impacting patient access to compounded GLP-1 medications.
Endocrinology
GLP-1 Therapies: New WHO Guidelines for Obesity Management
WHO's new guidelines endorse GLP-1 therapies for obesity management, emphasizing a comprehensive approach for better patient outcomes.
Endocrinology
FDA Approves Oral Semaglutide: New Dosing Guidelines for Obesity Management
FDA approves oral semaglutide for obesity management: new dosing guidelines without food restrictions.
Endocrinology
Insulin Icodec Reduces Dosing Frequency: Weekly vs Daily Basal Insulin in Type 2 Diabetes
Insulin icodec reduces dosing frequency: weekly vs daily basal insulin in type 2 diabetes, enhancing patient convenience and adherence.
Endocrinology
FDA Approves Insulin Icodec for Type 2 Diabetes: First Once-Weekly Basal Insulin
FDA approves insulin icodec for type 2 diabetes: first once-weekly basal insulin for improved glycemic control.
Endocrinology
FDA Approves Orforglipron for Obesity: Oral GLP-1 Receptor Agonist with No Food Restrictions
FDA approves orforglipron for obesity: oral GLP-1 receptor agonist with no food restrictions for weight management.
Endocrinology
FDA Approves Insulin Glargine-Aldy Biosimilar for Diabetes: Interchangeable with Lantus
FDA approves insulin glargine-aldy (Langlara) for diabetes: an interchangeable biosimilar to Lantus, improving patient access.
Endocrinology
Wegovy vs Rybelsus: GLP-1 Efficacy and Dosing Comparison for Obesity Management
Wegovy and Rybelsus: WHO guidelines confirm GLP-1 efficacy for obesity management, highlighting dosing and clinical implications.
Endocrinology
FDA Approves Afrezza for Pediatric Use: First Inhaled Insulin for Children with Diabetes
FDA approves Afrezza for pediatric use: first inhaled insulin for children with diabetes.
Endocrinology
FDA Approves Afrezza for Pediatric Diabetes: First Inhaled Insulin for Children and Adolescents
FDA approves Afrezza for pediatric diabetes: first inhaled insulin for children and adolescents with type 1 and type 2 diabetes.
Endocrinology
GLP-1 Receptor Agonists Reduce Cardiovascular Events: Key Insights for 2024
GLP-1 receptor agonists reduce cardiovascular events by 28% in patients with obesity and diabetes, emphasizing their role in treatment.
Endocrinology
WHO Releases New Guidelines on GLP-1 Therapies for Obesity Management: Comparing Tirzepatide, Semaglutide, and Orforglipron
WHO's guidelines on GLP-1 therapies for obesity management emphasize tirzepatide, semaglutide, and orforglipron's roles in treatment.
Endocrinology
FDA Approves Zepbound for Weight Management: Key Dosing Differences from Mounjaro
FDA approves Zepbound for chronic weight management, highlighting key dosing differences from Mounjaro for obesity treatment.
Endocrinology
Orforglipron vs Semaglutide: Efficacy Comparison in Weight Loss Without Food Restrictions
Orforglipron shows 7.5% weight loss efficacy compared to semaglutide in type 2 diabetes without food restrictions.
Endocrinology
FDA Approves Foundayo for Obesity: New GLP-1 Pill Option
FDA approves Foundayo for obesity: a new oral GLP-1 receptor agonist providing effective weight management options.
Endocrinology
FDA Approves Afrezza for Pediatric Use: First Inhaled Insulin for Type 1 and Type 2 Diabetes in Children
FDA approves Afrezza inhaled insulin for pediatric use: first needle-free option for type 1 and type 2 diabetes in children.
Endocrinology
Semaglutide: Key Differences Between Ozempic and Wegovy for Diabetes and Weight Loss
Explore the differences between Ozempic and Wegovy semaglutide for diabetes and weight loss, including dosing and clinical implications.
Endocrinology
FDA Approves Orforglipron for Chronic Weight Management in Adults with Obesity
FDA approves orforglipron for chronic weight management: a new oral GLP-1 receptor agonist for adults with obesity.
Endocrinology
FDA Approves Insulin Icodec for Type 2 Diabetes: First Once-Weekly Insulin
FDA approves insulin icodec for type 2 diabetes: first once-weekly insulin, improving glycemic control in adults.
Endocrinology
FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in Adults with Obesity
Semaglutide approved for cardiovascular risk reduction: 20% MACE reduction in adults with obesity.
Endocrinology
FDA Approves Orforglipron for Weight Loss: Oral GLP-1 Option for Obesity
FDA approves orforglipron for weight loss: a new oral GLP-1 option without food restrictions.
Endocrinology
WHO Updates GLP-1 Guidelines: Tirzepatide and Semaglutide for Obesity Management
WHO updates GLP-1 guidelines for obesity management: tirzepatide and semaglutide recommended for effective weight loss.
Endocrinology
FDA Approves Tirzepatide for Weight Management: Dosing Differences Between Mounjaro and Zepbound
FDA approves tirzepatide for weight management: dosing differences between Mounjaro and Zepbound.
Endocrinology
FDA Submits NDA for CagriSema: Fixed-Dose Combination of Cagrilintide and Semaglutide for Obesity Management
FDA submits NDA for CagriSema: a fixed-dose combination of cagrilintide and semaglutide for obesity management.
Endocrinology
FDA Approves Oral Semaglutide for Weight Management: 25 mg Dose for Obesity
FDA approves oral semaglutide (Wegovy) for weight management: 25 mg dose for obesity.
Endocrinology
Exploring the Expanding Role of GLP-1 Receptor Agonists Beyond Diabetes Management
Discover the expanding roles of GLP-1 receptor agonists in obesity, cardiovascular health, and neuroprotection beyond diabetes management.
Medical Research
Identify 5 Overeating Types for Targeted Interventions
Wearable sensors track eating habits to inform personalized obesity care and tailored interventions for better patient outcomes.
Healthcare Business
Targeted AFib Screening: Improved Outcomes
Learn how targeted atrial fibrillation screening can improve patient outcomes and reduce unnecessary tests in your practice, despite controversy over mass screening.
Healthcare Business
Boost Rural Healthcare with $10B Annual Funding
Discover how to access $50 billion in federal funding to enhance rural healthcare, improve provider recruitment, and adopt innovative technology.
Healthcare Business
Medicare Pay Cuts: 2.5% Reimbursement Reduction Looms
Proposed 2026 Medicare pay changes may cut reimbursement by 2.5% for thousands of procedures, affecting doctor pay and practice expenses.
Medical Research
Cut Diabetic Retinopathy Risk by 30% with GLP-1 Therapy
New research suggests GLP-1 receptor agonist drugs like semaglutide can significantly reduce diabetic retinopathy risk, a common diabetes complication.
Digital Health
Cut Pre-Op Admin Time with Digital Forms
Streamline pre-operative assessments with digital forms, reducing admin burden and enhancing patient engagement through remote access.
Medical Research
Eczema Patients at 30% Higher Risk of Suicidal Thoughts
New study reveals atopic eczema patients face increased risk of suicidal ideation, identifying key factors driving this elevated risk for better patient care.
Medical Research
Stroke Recovery Boosted by 7-Day Neural Progenitor Cell Transplant
Discover how transplanting hiPSC-NPCs 7 days post-stroke leads to long-term graft survival and potential for improved patient outcomes in stroke recovery.
Wellness
Reduce Blood Clot Risk 30% with Simple Desk Habits
Learn how to minimize the risk of deadly blood clots with simple changes to your daily desk routine and recognize the signs of venous thromboembolism.
Pharmaceutical
Vaccine Access Updates: What Physicians Need to Know
Stay informed on potential changes to US immunization policy and vaccine access, and how it may impact your practice and patient care.
Medical Research
New Treatment Cuts Vision Loss in LHON Patients
Discover how a novel treatment for Leber's Hereditary Optic Neuropathy (LHON) can help prevent sudden vision loss in patients, now approved for NHS use.